Evidence map›Paper›PMID 37865776›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

Autoimmune PaneLs as PrEdictors of Toxicity in Patients TReated with Immune Checkpoint InhibiTors (ALERT).

Sofia Genta, Katherine Lajkosz, Noelle R Yee, Pavlina Spiliopoulou, Alya Heirali, Aaron R Hansen, Lillian L Siu, Sam Saibil, Lee-Anne Stayner, Maryia Yanekina and 11 more

3 registry-linked trialsOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02644369 phase2active not recruitingnot on this map

Investigator-initiated Phase II Study of Pembrolizumab Immunological Response Evaluation

TypeinterventionalSponsorUniversity Health Network, TorontoRan2016 to 2026Enrolled100ConditionsSquamous Cell Cancer of Head and Neck, Triple Negative Breast Cancer, Epithelial Ovarian Cancer, Malignant MelanomaArmsPembrolizumab
NCT03686202 phase2 / phase3active not recruitingnot on this map

Feasibility Study of Microbial Ecosystem Therapeutics (MET-4) to Evaluate Effects of Fecal Microbiome in Patients on ImmunOtherapy (MET4-IO)

TypeinterventionalSponsorUniversity Health Network, TorontoRan2018 to 2026Enrolled65ConditionsAll Solid TumorsArmsMET-4
NCT04107311 active not recruitingnot on this map

Prospective Analysis of Intestinal Microbiome and Autoimmune Panels as Predictors of Toxicity in ImmunOncology Patients

TypeobservationalSponsorUniversity Health Network, TorontoRan2019 to 2027Enrolled120ConditionsSolid Tumor
3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 3 institutions in 1 country.

Sofia GentaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Katherine LajkoszDepartment of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Noelle R YeeToronto General Research Institute, University Health Network Toronto, Toronto, ON, Canada.
Pavlina SpiliopoulouDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Alya HeiraliToronto General Research Institute, University Health Network Toronto, Toronto, ON, Canada.
Aaron R HansenDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Lillian L SiuDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Sam SaibilDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Lee-Anne StaynerDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Maryia YanekinaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Maxwell B SauderDivision of Dematology, Department of Medicine, University of Toronto, Toronto, ON, Canada.
Sareh KeshavarziDepartment of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada.
Abdulazeez SalawuDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Olga VornicovaDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Marcus O ButlerDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Philippe L BedardDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Albiruni R Abdul RazakDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada.
Robert RottapelDepartment of Immunology, University of Toronto, Toronto, ON, Canada.
Andrzej ChruscinskiUniversity Health Network, University of Toronto, Toronto, ON, Canada.
Bryan CoburnToronto General Research Institute, University Health Network Toronto, Toronto, ON, Canada.
Anna SpreaficoDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada. anna.spreafico@uhn.ca.
Princess Margaret Cancer Centre · CAUniversity Health Network · CAUniversity of Toronto · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune-checkpoint inhibitors (ICI) can lead to immune-related adverse events (irAEs) in a significant proportion of patients. The mechanisms underlying irAEs development are mostly unknown and might involve multiple immune effectors, such as T cells, B cells and autoantibodies (AutoAb).

methodsWe used custom autoantigen (AutoAg) microarrays to profile AutoAb related to irAEs in patients receiving ICI. Plasma was collected before and after ICI from cancer patients participating in two clinical trials (NCT03686202, NCT02644369). A one-time collection was obtained from healthy controls for comparison. Custom arrays with 162 autoAg were used to detect IgG and IgM reactivities. Differences of median fluorescent intensity (MFI) were analyzed with Wilcoxon sign rank test and Kruskal-Wallis test. MFI 500 was used as threshold to define autoAb reactivity.

resultsA total of 114 patients and 14 healthy controls were included in this study. irAEs of grade (G) ≥ 2 occurred in 37/114 patients (32%). We observed a greater number of IgG and IgM reactivities in pre-ICI collections from patients versus healthy controls (62 vs 32 p < 0.001). Patients experiencing irAEs G ≥ 2 demonstrated pre-ICI IgG reactivity to a greater number of AutoAg than patients who did not develop irAEs (39 vs 33 p = 0.040). We observed post-treatment increase of IgM reactivities in subjects experiencing irAEs G ≥ 2 (29 vs 35, p = 0.021) and a decrease of IgG levels after steroids (38 vs 28, p = 0.009).

conclusionsOverall, these results support the potential role of autoAb in irAEs etiology and evolution. A prospective study is ongoing to validate our findings (NCT04107311).

Indexed as

AutoantigensImmune Checkpoint InhibitorsHumansImmunoglobulin GImmunoglobulin MProspective StudiesRetrospective StudiesAutoantigensImmune Checkpoint InhibitorsImmunoglobulin GImmunoglobulin M

Identifiers

PMID37865776
PMCPMC10589949
OpenAlexW4387843842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.